scholarly journals G protein-coupled receptors and the modification of FcɛRI-mediated mast cell activation

2007 ◽  
Vol 113 (2) ◽  
pp. 59-69 ◽  
Author(s):  
Hye Sun Kuehn ◽  
Alasdair M. Gilfillan
2017 ◽  
Vol 49 ◽  
pp. 6-12 ◽  
Author(s):  
Yangyang Yu ◽  
Yuanyuan Zhang ◽  
Yarui Zhang ◽  
Yihong Lai ◽  
Wenwen Chen ◽  
...  

Cells ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 1033
Author(s):  
Mukesh Kumar ◽  
Karthi Duraisamy ◽  
Billy Kwok Chong CHOW

Mas-related G-protein coupled receptor member X2 (MRGPRX2) is a class A GPCR expressed on mast cells. Mast cells are granulated tissue-resident cells known for host cell response, allergic response, and vascular homeostasis. Immunoglobulin E receptor (FcεRI)-mediated mast cell activation is a well-studied and recognized mechanism of allergy and hypersensitivity reactions. However, non-IgE-mediated mast cell activation is less explored and is not well recognized. After decades of uncertainty, MRGPRX2 was discovered as the receptor responsible for non-IgE-mediated mast cells activation. The puzzle of non-IgE-mediated pseudo-allergic reaction is unlocked by MRGPRX2, evidenced by a plethora of reported endogenous and exogenous MRGPRX2 agonists. MRGPRX2 is exclusively expressed on mast cells and exhibits varying affinity for many molecules such as antimicrobial host defense peptides, neuropeptides, and even US Food and Drug Administration-approved drugs. The discovery of MRGPRX2 has changed our understanding of mast cell biology and filled the missing link of the underlying mechanism of drug-induced MC degranulation and pseudo-allergic reactions. These non-canonical characteristics render MRGPRX2 an intriguing player in allergic diseases. In the present article, we reviewed the emerging role of MRGPRX2 as a non-IgE-mediated mechanism of mast cell activation in pseudo-allergic reactions. We have presented an overview of mast cells, their receptors, structural insight into MRGPRX2, MRGPRX2 agonists and antagonists, the crucial role of MRGPRX2 in pseudo-allergic reactions, current challenges, and the future research direction.


Immunity ◽  
2019 ◽  
Vol 50 (5) ◽  
pp. 1163-1171.e5 ◽  
Author(s):  
James Meixiong ◽  
Michael Anderson ◽  
Nathachit Limjunyawong ◽  
Mark F. Sabbagh ◽  
Eric Hu ◽  
...  

Molecules ◽  
2020 ◽  
Vol 25 (5) ◽  
pp. 1028 ◽  
Author(s):  
Mukesh Kumar ◽  
Kailash Singh ◽  
Karthi Duraisamy ◽  
Ahmed A. Allam ◽  
Jamaan Ajarem ◽  
...  

Anaphylactoid shock is a fatal hypersensitivity response caused by non-IgE mediated mast cell activation. These reactions are mediated by a family of G protein-coupled receptors (GPCRs) known as Mas related GPCRX2 (MRGPRX2). Several US FDA approved drugs which are used in day to day life have been reported to cause anaphylactoid shock. Surprisingly, no therapeutic drugs are available which can directly target MRGPRX2 for treatment of anaphylactoid shock. Genistein is a non-steroidal polyphenol known for its diverse physiological and pharmacological activities. In recent studies, Genistein has been reported for its anti-inflammatory activity on mast cells. However, the effects and mechanistic pathways of Genistein on anaphylactoid reaction remain unknown. In the present study, we designed a battery of in-vitro, in-silico and in-vivo experiments to evaluate the anti-anaphylactoid activity of Genistein in order to understand the possible molecular mechanisms of its action. The in-vitro results demonstrated the inhibitory activity of Genistein on MRGPRX2 activation. Further, a mouse model of anaphylactoid shock was used to evaluate the inhibitory activity of Genistein on blood vessel leakage and hind paw edema. Taken together, our findings have demonstrated a therapeutic potential of Genistein as a lead compound in the treatment of anaphylactoid shock via MRGPRX2.


Sign in / Sign up

Export Citation Format

Share Document